Dr. Vokes on the Standard of Care for Stage III NSCLC

Everett Vokes, MD
Published: Friday, Sep 01, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non–small cell lung cancer (NSCLC).

Patients with stage III NSCLC are treated for cure, which was achieved in 30% of newer clinical trials, explains Vokes. There is a standard therapy that is well defined for these patients. This includes either carboplatin and paclitaxel, cisplatin and pemetrexed, or cisplatin and etoposide, with concurrent radiation.

Adding other regimens to the standard of care has shown to have no significant impact on survival, states Vokes.
 
SELECTED
LANGUAGE


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non–small cell lung cancer (NSCLC).

Patients with stage III NSCLC are treated for cure, which was achieved in 30% of newer clinical trials, explains Vokes. There is a standard therapy that is well defined for these patients. This includes either carboplatin and paclitaxel, cisplatin and pemetrexed, or cisplatin and etoposide, with concurrent radiation.

Adding other regimens to the standard of care has shown to have no significant impact on survival, states Vokes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x